- Home
- IVAC vs ANL Comparison
IVAC vs ANL Comparison
Compare IVAC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVAC
- ANL
- Stock Information
- Founded
- IVAC 1990
- ANL 2004
- Country
- IVAC United States
- ANL Cayman Islands
- Employees
- IVAC N/A
- ANL N/A
- Industry
- IVAC Industrial Machinery/Components
- ANL
- Sector
- IVAC Technology
- ANL
- Exchange
- IVAC Nasdaq
- ANL Nasdaq
- Market Cap
- IVAC 88.8M
- ANL 72.7M
- IPO Year
- IVAC 1995
- ANL 2023
- Fundamental
- Price
- IVAC $2.65
- ANL $3.16
- Analyst Decision
- IVAC Hold
- ANL Strong Buy
- Analyst Count
- IVAC 1
- ANL 2
- Target Price
- IVAC N/A
- ANL $9.00
- AVG Volume (30 Days)
- IVAC 113.3K
- ANL 27.1K
- Earning Date
- IVAC 11-11-2024
- ANL 08-08-2024
- Dividend Yield
- IVAC N/A
- ANL N/A
- EPS Growth
- IVAC N/A
- ANL N/A
- EPS
- IVAC N/A
- ANL N/A
- Revenue
- IVAC $65,569,000.00
- ANL $5,000,000.00
- Revenue This Year
- IVAC N/A
- ANL N/A
- Revenue Next Year
- IVAC N/A
- ANL N/A
- P/E Ratio
- IVAC N/A
- ANL N/A
- Revenue Growth
- IVAC 28.52
- ANL N/A
- 52 Week Low
- IVAC $2.46
- ANL $1.85
- 52 Week High
- IVAC $4.57
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- IVAC 21.16
- ANL 66.74
- Support Level
- IVAC $2.46
- ANL $2.00
- Resistance Level
- IVAC $3.43
- ANL $3.89
- Average True Range (ATR)
- IVAC 0.15
- ANL 0.38
- MACD
- IVAC -0.09
- ANL 0.14
- Stochastic Oscillator
- IVAC 4.13
- ANL 61.74
About IVAC Intevac Inc.
Intevac Inc designs and develops high-productivity, thin-film processing systems. The company's production platforms are designed for high-volume manufacturing of substrates with precise thin-film properties, such as the hard disk drive, display cover panel. The Thin Film Equipment segment also previously designed, developed, and marketed manufacturing equipment for the photovoltaic solar cell and semiconductor packaging industries. Geographically, the majority of revenue is generated from Asia.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.